Health care stocks advanced late Friday afternoon, with the NYSE Health Care Index rising 1.8% and the Health Care Select Sector SPDR Fund (XLV) adding 1.5%.
The iShares Biotechnology ETF (IBB) climbed 1.5%.
In corporate news, DexCom (DXCM) shares jumped past 16%. The company late Thursday maintained its full-year revenue guidance after delivering a Q1 sales beat.
BrightSpring Health Services (BTSG) shares surged more than 16% after it reported Q1 adjusted EPS and revenue above analyst expectations and raised its 2025 revenue guidance.
Cytokinetics (CYTK) shares fell 12% after the US Food and Drug Administration extended the Prescription Drug User Fee Act action date to Dec. 26 for aficamten in obstructive hypertrophic cardiomyopathy in the previous day.
Novo Nordisk (NVO) shares popped 5.7% after Health Canada accepted for review a supplemental new drug submission for semaglutide 2.4 mg as a once weekly treatment for people with metabolic dysfunction-associated steatohepatitis.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。